173 related articles for article (PubMed ID: 15881481)
21. Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention.
Greenhalgh J; Bagust A; Boland A; Saborido CM; Fleeman N; McLeod C; Dundar Y; Dickson R; Proudlove C; Kolamunnage-Dona R; Fisher M
Health Technol Assess; 2010 May; 14 Suppl 1():31-8. PubMed ID: 20507801
[TBL] [Abstract][Full Text] [Related]
22. The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden.
Lindgren P; Stenestrand U; Malmberg K; Jönsson B
Clin Ther; 2005 Jan; 27(1):100-10. PubMed ID: 15763611
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of clopidogrel-aspirin versus aspirin alone for acute transient ischemic attack and minor stroke.
Pan Y; Wang A; Liu G; Zhao X; Meng X; Zhao K; Liu L; Wang C; Johnston SC; Wang Y; Wang Y;
J Am Heart Assoc; 2014 Jun; 3(3):e000912. PubMed ID: 24904018
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials.
Berg J; Lindgren P; Spiesser J; Parry D; Jönsson B
Clin Ther; 2007 Jun; 29(6):1184-202. PubMed ID: 17692733
[TBL] [Abstract][Full Text] [Related]
25. [Cost-effectiveness of clopidogrel vs. aspirin treatment in high-risk acute coronary syndrome patients in Denmark].
Heeg B; van Gestel A; Hout Bv; Olsen J; Haghfelt TH
Ugeskr Laeger; 2006 Aug; 168(35):2911-5. PubMed ID: 16982022
[TBL] [Abstract][Full Text] [Related]
26. Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis.
Shah H; Gondek K
Clin Ther; 2000 Mar; 22(3):362-70; discussion 360-1. PubMed ID: 10963290
[TBL] [Abstract][Full Text] [Related]
27. Clopidogrel Versus Aspirin for the Treatment of Acute Coronary Syndrome After a 12-Month Dual Antiplatelet Therapy: A Cost-effectiveness Analysis From China Payer's Perspective.
Zhang L; Lin Z; Yin H; Liu J; Xuan J
Clin Ther; 2018 Dec; 40(12):2125-2137. PubMed ID: 30470579
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of ticagrelor versus clopidogrel for the prevention of atherothrombotic events in adult patients with acute coronary syndrome in Germany.
Theidel U; Asseburg C; Giannitsis E; Katus H
Clin Res Cardiol; 2013 Jun; 102(6):447-58. PubMed ID: 23474908
[TBL] [Abstract][Full Text] [Related]
29. Long-term clopidogrel therapy in patients receiving percutaneous coronary intervention.
Heeg BM; Peters RJ; Botteman M; van Hout BA
Pharmacoeconomics; 2007; 25(9):769-82. PubMed ID: 17803335
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of clopidogrel in acute coronary syndromes in Canada: a long-term analysis based on the CURE trial.
Kolm P; Yuan Y; Veledar E; Mehta SR; O'Brien JA; Weintraub WS
Can J Cardiol; 2007 Nov; 23(13):1037-42. PubMed ID: 17985004
[TBL] [Abstract][Full Text] [Related]
31. Prasugrel vs clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a model-based cost-effectiveness analysis for Germany, Sweden, the Netherlands, and Turkey.
Davies A; Bakhai A; Schmitt C; Barrett A; Graham-Clarke P; Sculpher M
J Med Econ; 2013; 16(4):510-21. PubMed ID: 23339464
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of 12-month treatment with ticagrelor compared with clopidogrel in the management of acute coronary syndromes.
Liew D; De Abreu Lourenço R; Adena M; Chim L; Aylward P
Clin Ther; 2013 Aug; 35(8):1110-1117.e9. PubMed ID: 23891361
[TBL] [Abstract][Full Text] [Related]
33. Direct healthcare costs and cost-effectiveness of acute coronary syndrome secondary prevention with ticagrelor compared to clopidogrel: economic evaluation from the public payer's perspective in Poland based on the PLATO trial results.
Pawęska J; Macioch T; Perkowski P; Budaj A; Niewada M
Kardiol Pol; 2014; 72(9):823-30. PubMed ID: 24846362
[TBL] [Abstract][Full Text] [Related]
34. Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy.
Janzon M; James S; Cannon CP; Storey RF; Mellström C; Nicolau JC; Wallentin L; Henriksson M
Heart; 2015 Jan; 101(2):119-25. PubMed ID: 25227704
[TBL] [Abstract][Full Text] [Related]
35. The value of clopidogrel versus aspirin in reducing atherothrombotic events: the CAPRIE study.
Durand-Zaleski I; Bertrand M
Pharmacoeconomics; 2004; 22 Suppl 4():19-27. PubMed ID: 15876009
[TBL] [Abstract][Full Text] [Related]
36. Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis.
Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Fleeman N; McEntee J; Dundar Y; Richardson M; Fisher M
Health Technol Assess; 2015 Apr; 19(29):1-130. PubMed ID: 25896573
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of antiplatelet agents in secondary stroke prevention: the limits of certainty.
Matchar DB; Samsa GP; Liu S
Value Health; 2005; 8(5):572-80. PubMed ID: 16176495
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of ticagrelor and generic clopidogrel in patients with acute coronary syndrome in Switzerland.
Gasche D; Ulle T; Meier B; Greiner RA
Swiss Med Wkly; 2013; 143():w13851. PubMed ID: 24089294
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack.
Sarasin FP; Gaspoz JM; Bounameaux H
Arch Intern Med; 2000 Oct; 160(18):2773-8. PubMed ID: 11025787
[TBL] [Abstract][Full Text] [Related]
40. Using triple antiplatelet therapy in patients with non-ST elevation acute coronary syndrome managed invasively: a cost-effectiveness analysis.
Latour-Pérez J; de Miguel Balsa E; Betegón L; Badia X
Value Health; 2008; 11(5):853-61. PubMed ID: 18489507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
